Minocycline and autoimmunity.
Minocycline is the most widely prescribed systemic antibiotic for the management of acne. In the past several years, increasing attention has been paid to the drug, both for its potential use as a disease-modifying antirheumatic agent and for its propensity to engender untoward autoimmune reactions, including serum sickness-like disease, drug-induced lupus, and autoimmune hepatitis. This paper reviews the evidence for minocycline as an anti-inflammatory and immunomodulatory agent, its utility in the treatment of rheumatoid arthritis, and the spectrum of adverse reactions that have been ascribed to the drug in the past 5 years.
Eichenfield
A H
AH
Division of Pediatric Rheumatology, Mount Sinai School of Medicine, New York, New York 10029-6574, USA.
D000152:Acne Vulgaris / Q000188:drug therapy; D000818:Animals; D000900:Anti-Bacterial Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D001168:Arthritis / Q000139:chemically induced; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D001327:Autoimmune Diseases / Q000139:chemically induced; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology; D004342:Drug Hypersensitivity / Q000209:etiology; D005260:Female; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000139:chemically induced; D008297:Male; D008911:Minocycline / Q000009:adverse effects* / Q000627:therapeutic use*; D014657:Vasculitis / Q000139:chemically induced
D000900:Anti-Bacterial Agents; D008911:Minocycline